HDAC-IN-40 |
| Katalog-Nr.GC66052 |
HDAC-IN-40 ist ein potenter HDAC-Inhibitor auf Alkoxyamidbasis mit Ki-Werten von 60 nM und 30 nM fÜr HDAC2 bzw. HDAC6. HDAC-IN-40 hatte Antitumorwirkungen.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2463198-51-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
HDAC-IN-40 is a potent alkoxyamide-based HDAC inhibitor with Ki values of 60 nM and 30 nM for HDAC2 and HDAC6, respectively. HDAC-IN-40 had antitumor effects[1].
HDAC-IN-40 (Compound 13d) shows antiproliferative activity against the cell line A2780 and Cal27 with IC50 values of 0.89 µM and 0.72 µM, respectively[1].
HDAC-IN-40 induces accumulation of acetyl α-tubulin in Cal27 and Cal27CisR[1].
HDAC-IN-40 enhances the Cisplatin-induced cytotoxicity via caspase-3/7 activation[1].
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *